MyoKardia, a clinical-stage biotech developing therapies for heritable cardiomyopathies, filed on Monday with the SEC to raise up to $86 million in an initial public offering.
The South San Francisco, CA-based company, which was founded in 2012 and booked $13 million in sales for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol MYOK. MyoKardia initially filed confidentially on 8/20/2015. Credit Suisse, Cowen & Company and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
